Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by CEL-SCI Corporation

< Previous 1 2 Next >
CEL-SCI Files Request With the UK’s MHRA Regarding Path to Approval for Multikine in the Treatment of Head & Neck Cancer
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI Submits Scientific Advice Filing to European Medicines Agency (EMA) for Multikine in the Treatment of Head & Neck Cancer
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI Corporation Reports Third Quarter Fiscal 2023 Financial Results
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI Announces Closing of Public Offering
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI Announces Pricing of Public Offering
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI Announces Proposed Public Offering of Common Stock
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI Concludes Positive Meeting With U.S. FDA Concerning Multikine’s Approval for Head & Neck Cancer
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI Reports Phase 3 Tumor PD-L1 Biomarker Data Demonstrate Multikine’s Increased Efficacy and Points to Potential for Combination With Checkpoint Inhibitors for Head & Neck Cancer
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI to Present Novel Data at AHNS 11th International Conference on Head and Neck Cancer—New Patent to Be Filed
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
Histopathology and Tumor Biomarker Analysis Confirm CEL-SCI’s Multikine Significantly Prolonged Overall Survival in Head & Neck Cancer—Phase 3 Data Presented at ESTRO 2023
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI Corporation Reports Second Quarter Fiscal 2023 Financial Results
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI Announces $1.35 Million Underwritten Confidentially Marketed Public Offering of Common Stock
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI to Pursue Canada’s Conditional Approval Pathway for Multikine in the Treatment of Head & Neck Cancer
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI’s Multikine Phase 3 Cancer Study Shows 43% Survival Extension
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI to Present New Phase 3 Data at European Congress on Head & Neck Oncology
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI Corporation Reports First Quarter Fiscal 2023 Financial Results
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI Reports Fiscal 2022 Financial Results and Clinical & Corporate Developments
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI Corporation Issues Letter to Shareholders
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI’S Multikine Reduced 5-year Death Rate From 54% to 22% in Phase 3 Study Patients Who Were Early Tumor Responders Prior to Any Standard of Care Treatment
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI’S Phase 3 Data Presented at ESMO 2022: Neoadjuvant Multikine Achieved Groundbreaking Tumor Response & Extended Overall Survival in Locally Advanced Head and Neck Cancer
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI Corporation Issues Letter to Shareholders
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI Corporation Announces Phase 3 Multikine® Head and Neck Cancer Results Posted on Clinicaltrials.gov
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI Corporation Reports Third Quarter Fiscal 2022 Financial Results
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI Appoints Dr. Gail Naughton to Its Board of Directors
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI Corporation Announces Reddit AMA with Geert Kersten
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI Corporation to Present at LD Micro Invitational
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI Presents Phase 3 Multikine Head & Neck Cancer Data at ASCO
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI Announces Publication of ASCO 2022 Abstracts
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI Corporation Reports Second Quarter Fiscal 2022 Financial Results
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI Announces Acceptance of Abstracts to ASCO 2022
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.